The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R et al. Expert Rev Hematol. 2016 Jul 22. [Epub ahead of print].

A new era of immune therapy in multiple myeloma.
Tai YT et al. Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856.

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden Hospital experience.
Sriskandarajah P et al. Leuk Lymphoma. 2016 Jul 20:1-4. [Epub ahead of print].

Targeting PADI2 could stop the progression of myeloma.
Tanday S et al. Lancet Oncol. 2016 Jul 14. pii: S1470-2045(16)30314-X. doi: 10.1016/S1470-2045(16)30314-X. [Epub ahead of print].

Elotuzumab for the treatment of multiple myeloma.
Wang Y et al. J Hematol Oncol. 2016 Jul 15;9(1):55. doi: 10.1186/s13045-016-0284-z.

Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.
Clark CA et al. Am J Hematol. 2016 Jul 14. doi: 10.1002/ajh.24478. [Epub ahead of print].

Does cognitive decline decrease health utility value in older adult patients with cancer?
Akechi T et al. Psychogeriatrics. 2016 Jul 13. doi: 10.1111/psyg.12205. [Epub ahead of print].

Multiple myeloma–translation of trial results into reality.
Moreau P et al. Lancet. 2016 Jul 9;388(10040):111-3. doi: 10.1016/S0140-6736(16)30954-0.

Multiple myeloma: patient outcomes in real-world practice.
Yong K et al. Br J Haematol. 2016 Jul 13. doi: 10.1111/bjh.14213. [Epub ahead of print].

Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival.
Wang GR et al. Acta Haematol. 2016 Jul 14;136(3):140-146. [Epub ahead of print].

Multiple myeloma: disease response assessment
Zamagni E et al. Expert Rev Hematol. 2016 Jul 13. [Epub ahead of print].

Hematologic malignancies during pregnancy: A review.
Mahmoud HK et al. J Adv Res. 2016 Jul;7(4):589-96. doi: 10.1016/j.jare.2016.02.001. Epub 2016 Feb 8.

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.
Mailankody S et al. Oncologist. 2016 Jul 8. pii: theoncologist.2016-0086. [Epub ahead of print].

Lifestyle in Multiple Myeloma – a longitudinal cohort study protocol.
Heinrich M et al. BMC Cancer. 2016 Jul 4;16(1):387. doi: 10.1186/s12885-016-2407-x.

Autologous stem cell transplant for multiple myeloma patients 70 years or older.
Muchtar E et al. Bone Marrow Transplant. 2016 Jul 4. doi: 10.1038/bmt.2016.174. [Epub ahead of print].

The role of SLAMF7 in multiple myeloma: impact on therapy.
Boudreault JS et al. Expert Rev Clin Immunol. 2016 Jul 18:1-9. [Epub ahead of print].

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L et al. J Hematol Oncol. 2016 Jun 30;9(1):51. doi: 10.1186/s13045-016-0283-0.

Novel agents in the treatment of multiple myeloma: a review about the future.
Naymagon L et al. J Hematol Oncol. 2016 Jun 30;9(1):52. doi: 10.1186/s13045-016-0282-1.

Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN).
Li J et al. Cancer Causes Control. 2016 Aug;27(8):1019-26. doi: 10.1007/s10552-016-0780-z. Epub 2016 Jun 28.

Monoclonal antibodies for treating multiple myeloma – a new era, new safety considerations?
Oliva S et al. Expert Opin Drug Saf. 2016 Jul 5:1-6. [Epub ahead of print].

Management of high-risk Myeloma: an evidence-based review of treatment strategies.
Lehners N et al. Expert Rev Hematol. 2016 Jul 4:1-13. [Epub ahead of print].